{"paper_id":"39776f45-e558-43dd-87ff-8e0a698722dc","body_text":"Access this article\nWe’re sorry, something doesn't seem to be working properly.\nPlease try refreshing the page. If that doesn't work, please contact support so we can address the problem.\nReferences\nSourial S, Tempest N, Hapangama DK (2014) Theories on the pathogenesis of endometriosis. Int J Reprod Med 2014:179515. https://doi.org/10.1155/2014/179515\nZhou WJ, Yang HL, Shao J, Mei J, Chang KK, Zhu R, Li MQ (2019) Anti-inflammatory cytokines in endometriosis. Cell Mol Life Sci 76(11):2111–2132. https://doi.org/10.1007/s00018-019-03056-x\nOnalan G, Tohma YA, Zeyneloglu HB (2018) Effect of etanercept on the success of assisted reproductive technology in patients with endometrioma. Gynecol Obstet Invest 83(4):358–364. https://doi.org/10.1159/000484895\nDull AM, Moga MA, Dimienescu OG, Sechel G, Burtea V, Anastasiu CV (2019) Therapeutic approaches of resveratrol on endometriosis via anti-inflammatory and anti-angiogenic pathways. Molecules. https://doi.org/10.3390/molecules24040667\nRosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, Group MS (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431. https://doi.org/10.1056/NEJMoa054481\nKourlas H, Abrams P (2007) Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 29(9):1850–1861. https://doi.org/10.1016/j.clinthera.2007.09.008\nVodolazkaia A, Yesilyurt BT, Kyama CM, Bokor A, Schols D, Huskens D, Meuleman C, Peeraer K, Tomassetti C, Bossuyt X, Lambrechts D, D’Hooghe T, Fassbender A (2016) Vascular endothelial growth factor pathway in endometriosis: genetic variants and plasma biomarkers. Fertil Steril 105(4):988–996. https://doi.org/10.1016/j.fertnstert.2015.12.016\nSevket O, Sevket A, Buyukpinarbasili N, Molla T, Kilic G, Ates S, Dansuk R (2013) The effects of ranibizumab on surgically induced endometriosis in a rat model: a preliminary study. Reprod Sci 20(10):1224–1229. https://doi.org/10.1177/1933719113483012\nKates SL, Ackert-Bicknell CL (2016) How do bisphosphonates affect fracture healing? Injury 47(Suppl 1):S65-68. https://doi.org/10.1016/S0020-1383(16)30015-8\nIshtiaq S, Edwards S, Sankaralingam A, Evans BA, Elford C, Frost ML, Fogelman I, Hampson G (2015) The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells. Cytokine 71(2):154–160. https://doi.org/10.1016/j.cyto.2014.10.025\nVan Acker HH, Anguille S, Willemen Y, Smits EL, Van Tendeloo VF (2016) Bisphosphonates for cancer treatment: mechanisms of action and lessons from clinical trials. Pharmacol Ther 158:24–40. https://doi.org/10.1016/j.pharmthera.2015.11.008\nGao SY, Zheng GS, Wang L, Liang YJ, Zhang SE, Lao XM, Li K, Liao GQ (2017) Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB. PLoS ONE 12(6):e0179248. https://doi.org/10.1371/journal.pone.0179248\nVernon MW, Wilson EA (1985) Studies on the surgical induction of endometriosis in the rat. Fertil Steril 44(5):684–694\nUygur D, Aytan H, Zergeroglu S, Batioglu S (2006) Leflunomide–an immunomodulator—induces regression of endometrial explants in a rat model of endometriosis. J Soc Gynecol Investig 13(5):378–383. https://doi.org/10.1016/j.jsgi.2006.03.006\nKatsuki Y, Takano Y, Futamura Y, Shibutani Y, Aoki D, Udagawa Y, Nozawa S (1998) Effects of dienogest, a synthetic steroid, on experimental endometriosis in rats. Eur J Endocrinol 138(2):216–226\nDaubine F, Le Gall C, Gasser J, Green J, Clezardin P (2007) Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 99(4):322–330. https://doi.org/10.1093/jnci/djk054\nMota A, Carneiro A, Breda J, Rosas V, Magalhaes A, Silva R, Falcao-Reis F (2012) Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity. Case Rep Ophthalmol 3(1):136–141. https://doi.org/10.1159/000338623\nKeenan JA, Williams-Boyce PK, Massey PJ, Chen TT, Caudle MR, Bukovsky A (1999) Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril 72(1):135–141. https://doi.org/10.1016/s0015-0282(99)00157-0\nMari-Alexandre J, Barcelo-Molina M, Belmonte-Lopez E, Garcia-Oms J, Estelles A, Braza-Boils A, Gilabert-Estelles J (2018) Micro-RNA profile and proteins in peritoneal fluid from women with endometriosis: their relationship with sterility. Fertil Steril 109(4):675-684.e672. https://doi.org/10.1016/j.fertnstert.2017.11.036\nRudzitis-Auth J, Menger MD, Laschke MW (2013) Resveratrol is a potent inhibitor of vascularization and cell proliferation in experimental endometriosis. Hum Reprod 28(5):1339–1347. https://doi.org/10.1093/humrep/det031\nNap AW, Dunselman GA, Griffioen AW, Mayo KH, Evers JL, Groothuis PG (2005) Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane. Fertil Steril 83(3):793–795. https://doi.org/10.1016/j.fertnstert.2004.06.080\nBecker CM, Sampson DA, Short SM, Javaherian K, Folkman J, D’Amato RJ (2006) Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model. Fertil Steril 85(1):71–77. https://doi.org/10.1016/j.fertnstert.2005.07.1290\nJiang HQ, Li YL, Zou J (2007) Effect of recombinant human endostatin on endometriosis in mice. Chin Med J (Engl) 120(14):1241–1246\nClezardin P, Ebetino FH, Fournier PG (2005) Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 65(12):4971–4974. https://doi.org/10.1158/0008-5472.CAN-05-0264\nWood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302(3):1055–1061. https://doi.org/10.1124/jpet.102.035295\nLi XY, Lin YC, Huang WL, Wang HB, Lin W, Hong CQ, Chen JY (2011) Inhibitory effects of zoledronic acid on cell proliferation and invasion in human nasopharyngeal carcinoma cell line HNE1. Zhonghua Yi Xue Za Zhi 91(32):2278–2282\nTabibzadeh S (1995) Signals and molecular pathways involved in apoptosis, with special emphasis on human endometrium. Hum Reprod Update 1(4):303–323. https://doi.org/10.1093/humupd/1.4.303\nOkamoto S, Jiang Y, Kawamura K, Shingyoji M, Tada Y, Sekine I, Takiguchi Y, Tatsumi K, Kobayashi H, Shimada H, Hiroshima K, Tagawa M (2014) Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions. Cell Death Dis 5:e1517. https://doi.org/10.1038/cddis.2014.475\nJagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84(8):1126–1134. https://doi.org/10.1054/bjoc.2001.1727\nTakahashi R, Shimazaki C, Inaba T, Okano A, Hatsuse M, Okamoto A, Hirai H, Ashihara E, Nakagawa M (2001) A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leuk Res 25(1):77–83\nAcknowledgements\nThe authors would like to thank to Yusuf Aytac Tohma for his contribution to the critical review of the study.\nFunding\nThis study was funded by The Technological and Scientific Research Council of Turkey (TUBITAK) (213S002).\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEthics declarations\nConflict of interest\nThe authors declare that have no conflicts of interest.\nEthical approval\nThis study was approved by the Experimental Animals Ethics Committee of Ege University (2013-018).\nAdditional information\nPublisher's Note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nThis study was represented as oral presentation in 33rd Annual Meeting of the European Society of Human Reproduction and Embryology held in Palexpo in Geneva, Switzerland, 2–5 July, 2017.\nRights and permissions\nAbout this article\nCite this article\nUreyen Ozdemir, E., Adali, E., Islimye Taskin, M. et al. Effects of ranibizumab and zoledronic acid on endometriosis in a rat model. Arch Gynecol Obstet 306, 1399–1405 (2022). https://doi.org/10.1007/s00404-021-06393-0\nReceived:\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s00404-021-06393-0","source_license":"CC0","license_restricted":false}